Related Experiment Videos
CA19-9: a possible serum marker for embryonal carcinoma
1Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan.
Urologia Internationalis
|January 1, 1997
Summary
Serum CA19-9 may indicate embryonal carcinoma in male patients. Elevated levels normalized with treatment, suggesting CA19-9 as a potential biomarker for this germ cell tumor.
Area of Science:
- Oncology
- Biochemistry
Background:
- Germ cell tumors (GCTs) are malignancies originating from germ cells.
- Accurate tumor markers are crucial for diagnosis and monitoring of GCTs.
Purpose of the Study:
- To investigate the utility of carbohydrate antigen 19-9 (CA19-9) as a serum marker for embryonal carcinoma.
- To correlate serum CA19-9 levels with clinical response to treatment in male patients with GCTs.
Main Methods:
- Serial measurement of serum CA19-9 in 18 male patients diagnosed with GCT.
- Immunohistochemical staining of GCT specimens using a monoclonal antibody against CA19-9.
Main Results:
- Elevated serum CA19-9 was observed in 5 out of 8 patients with embryonal carcinoma.
- Serum CA19-9 levels decreased to normal ranges correlating with treatment response.
- Immunohistochemistry revealed consistent CA19-9 positivity in embryonal carcinomas and mature teratomas, faint positivity in seminomas, and negativity in choriocarcinomas, yolk sac tumors, and immature teratomas.
Conclusions:
- Serum CA19-9 demonstrates potential as a valuable biomarker for detecting and monitoring embryonal carcinoma.
- The antigen's expression pattern in various GCT subtypes aids in differential diagnosis.